Today: 7 February 2026
Subscribe
Browse Category

Mergers and Acquisitions News 7 January 2026 - 7 February 2026

Confluent stock holds near $31 IBM bid as new SEC filing details shareholder suits, Feb. 12 vote

Confluent stock holds near $31 IBM bid as new SEC filing details shareholder suits, Feb. 12 vote

Confluent shares edged up 0.1% to $30.37 Thursday after the company disclosed new details on shareholder litigation tied to its pending $11 billion IBM acquisition. The stock traded about 2% below IBM’s $31-per-share offer as investors watched for the Feb. 12 shareholder vote and Confluent’s earnings report on Feb. 11.
5 February 2026
···
Confluent stock price today: CFLT stays just under IBM’s $31 offer as February deadlines near

Confluent stock price today: CFLT stays just under IBM’s $31 offer as February deadlines near

Confluent shares traded at $30.42 Wednesday, about 2% below IBM’s $31-per-share cash offer, as investors await a February 12 shareholder vote on the $11 billion deal. The U.S. antitrust waiting period expired January 12, but the merger still needs shareholder and further regulatory approval. Confluent will report earnings February 11 without a call or outlook. Trading volume surged to 53 million shares ahead of key dates.
4 February 2026
···
GE Vernova stock price hits new high as Prolec GE buyout closes and bond sale starts

GE Vernova stock price hits new high as Prolec GE buyout closes and bond sale starts

GE Vernova closed its $5.28 billion purchase of the remaining Prolec GE stake from Xignux and launched a senior notes offering to help fund the deal. Shares rose 4% to $754.97, holding steady after hours. Fitch and S&P rated the planned debt investment grade. The company’s wind segment reported a $598 million loss for 2025 and expects further losses in 2026.
3 February 2026
···
Eldorado Gold stock sinks on Foran Mining buyout: what investors watch next

Eldorado Gold stock sinks on Foran Mining buyout: what investors watch next

Eldorado Gold shares fell about 9% Monday after announcing a deal to acquire Foran Mining, expanding its copper portfolio. The stock dropped $4.03 to $38.89 in New York trading. Foran shareholders will receive 0.1128 Eldorado shares plus C$0.01 per share, with the merger expected to close in Q2 pending approvals. Eldorado reports full-year earnings Feb. 19.
2 February 2026
······
Beazley share price steadies, but Zurich bid clock keeps traders on edge heading into Monday

Beazley share price steadies, but Zurich bid clock keeps traders on edge heading into Monday

Beazley shares closed Friday at 1,133 pence, up 0.09%, staying well below Zurich’s 1,280-pence takeover bid. The gap reflects investor uncertainty as Zurich’s £7.67 billion offer remains only a proposal. Barclays and Caxton Associates disclosed new positions, while traders await further takeover filings and Beazley’s results on March 4. Zurich faces a Feb. 16 deadline to formalize or withdraw its bid.
31 January 2026
···
Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott Laboratories shares rose 2.6% to $108.89 Friday after missing revenue targets and guiding first-quarter adjusted EPS below analyst estimates. Freedom Capital Markets upgraded the stock to “buy” but cut its price target. Abbott expects to close its $23 billion Exact Sciences acquisition by Q2 2026. Exact Sciences shareholders will vote on the merger Feb. 20.
30 January 2026
···
Coeur Mining (CDE) slides as silver ETF rush collides with New Gold deal vote

Coeur Mining (CDE) slides as silver ETF rush collides with New Gold deal vote

Coeur Mining shares fell 2.5% to $24.81 Tuesday amid heavy trading and volatility in silver prices. Retail investors bought about $171 million of iShares Silver Trust on Monday, according to Vanda Research. Coeur shareholders are voting on proposals for its planned all-stock acquisition of New Gold. Spot silver jumped 4% to $108.05 an ounce after hitting a record high Monday.
27 January 2026
·····
Beazley share price in focus as Zurich’s bid clock ticks toward Feb. 16 — what London traders watch

Beazley share price in focus as Zurich’s bid clock ticks toward Feb. 16 — what London traders watch

Beazley closed Friday at 1,152 pence, up 3.23%, as Zurich’s 1,280 pence-per-share cash offer remains on the table ahead of a Feb. 16 deadline. Beazley’s board rejected the bid, calling it undervalued. Shares dropped sharply after the rejection but recovered by the close. Investors await any revised offer and Beazley’s results due March 4.
26 January 2026
·
Beazley shares rise again as Zurich bid deadline nears — what to watch when London reopens

Beazley shares rise again as Zurich bid deadline nears — what to watch when London reopens

Beazley shares rose 3.2% to £11.52 on Friday but remain below Zurich’s 1,280p takeover offer, which the board rejected as too low. Zurich faces a Feb. 16 deadline to raise its bid or walk away. Beazley’s board cited a previous 1,315p approach and set March 4 for full-year results. Investors are watching for any revised offer or new bidders.
24 January 2026
···
Kenvue (KVUE) stock price barely budges as Kimberly-Clark deal vote nears

Kenvue (KVUE) stock price barely budges as Kimberly-Clark deal vote nears

Kenvue shares rose 0.1% to $17.77 Friday as investors await a Jan. 29 shareholder vote on its proposed sale to Kimberly-Clark. The deal would give Kenvue holders $3.50 in cash and 0.14625 Kimberly-Clark shares per Kenvue share. Institutional Shareholder Services recommended approval but cited litigation risks. Trading volume has surged ahead of the vote.
23 January 2026
···
Netflix flips to an all-cash $82.7 billion Warner Bros. Discovery bid as Paramount clock ticks

Netflix flips to an all-cash $82.7 billion Warner Bros. Discovery bid as Paramount clock ticks

Netflix switched to an all-cash $27.75-per-share bid for Warner Bros. Discovery’s studio and streaming units, keeping the total value at $82.7 billion. The move comes just before Paramount Skydance’s $30-per-share tender offer expires Jan. 21. Warner set a $1.33–$6.86 per-share valuation for the Discovery Global spinoff. Netflix shares rose 1.3% in premarket trading; Warner slipped.
20 January 2026
···
Kenvue stock edges up as Kimberly-Clark vote nears — the deal spread traders are watching

Kenvue stock edges up as Kimberly-Clark vote nears — the deal spread traders are watching

Kenvue shares rose 0.4% to $17.08 in mid-morning trading after Kimberly-Clark filed new deal documents with U.S. regulators. The stock remains about 5% below the value implied by the pending cash-and-stock takeover. Kenvue shareholders are set to vote on the deal Jan. 29. The transaction’s value fluctuates with Kimberly-Clark’s share price.
14 January 2026
···
Netflix stock slips as all-cash Warner Bros bid talk swirls, with earnings days away

Netflix stock slips as all-cash Warner Bros bid talk swirls, with earnings days away

Netflix shares fell 1.6% Wednesday as investors weighed reports it may switch to an all-cash bid for Warner Bros Discovery’s studio and streaming assets, valued at $82.7 billion. Paramount Skydance, offering $108.4 billion for all of Warner Bros, escalated its challenge with a lawsuit and board nominations. Warner Bros dismissed the lawsuit as meritless. Netflix’s quarterly results are due January 20.
14 January 2026
····
Amphenol stock rises as Barclays, Citi and Truist lift targets after CommScope deal closes

Amphenol stock rises as Barclays, Citi and Truist lift targets after CommScope deal closes

Amphenol shares rose 2.2% to $148.28 Tuesday, bucking a broader market decline after finalizing its $10.5 billion acquisition of CommScope’s CCS business. Analysts at Barclays, Citi, and Truist raised price targets, citing expected sales growth and stronger demand. The company projects CCS will add $4.1 billion in 2026 sales and $0.15 to EPS, excluding costs. Quarterly earnings are due Jan. 28.
13 January 2026
···
GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

GSK shares slipped 0.03% to 1,885.5 pence in early London trading Monday, as investors awaited the company’s appearance at the J.P. Morgan Healthcare Conference in San Francisco on Tuesday. GSK’s ADRs closed up 0.3% in the U.S. at $50.39. Traders are watching for updates ahead of GSK’s full-year results due February 4.
12 January 2026
····
Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck shares fell 0.4% to $110.53 after reports it is in talks to acquire Revolution Medicines for up to $32 billion. The company faces new scrutiny over its Gardasil and RotaTeq vaccines after U.S. policy changes, with analysts estimating a $2 billion annual revenue impact. Wolfe Research upgraded Merck, citing progress on a subcutaneous version of Keytruda.
10 January 2026
····
D-Wave Quantum stock (QBTS) slides after $550 million Quantum Circuits deal puts dilution in focus

D-Wave Quantum stock (QBTS) slides after $550 million Quantum Circuits deal puts dilution in focus

D-Wave Quantum shares fell 3.4% to $30.20 after announcing a $550 million deal to acquire Quantum Circuits, split between $250 million cash and $300 million in stock. The agreement uses a VWAP collar to set share count and requires antitrust and NYSE approval. The deal aims to bring superconducting gate-model systems to market in 2026. Trading volume reached 36.5 million shares.
8 January 2026
···
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck shares slipped 0.3% to $108.59 after it completed its tender offer for Cidara Therapeutics and expects to finalize the $9.2 billion acquisition later Wednesday. The deal will add about $9 billion to 2026 R&D expenses and reduce earnings per share by 30 cents in the first year. Merck also began a Phase 3 lung-cancer trial of calderasib with Keytruda QLEX. U.S. officials updated HPV and rotavirus vaccine guidance this week.
7 January 2026
·····
1 2 3 … 6

Stock Market Today

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company projected about $200 billion in 2026 capital expenditures, triggering investor concern over AI spending. The stock had already dropped 11.5% after-hours Thursday. Amazon forecast Q1 net sales of $173.5–$178.5 billion and operating income of $16.5–$21.5 billion. Analyst Gil Luria downgraded Amazon, citing rising investment as its cloud lead narrows.
AMD stock jumps 8% in chip rebound — what investors are watching before Monday

AMD stock jumps 8% in chip rebound — what investors are watching before Monday

7 February 2026
AMD shares jumped 8.2% to $208.44 Friday, trading on heavy volume as chip stocks rebounded and the Dow closed above 50,000 for the first time. The Philadelphia Semiconductor Index rose 5.7% after Amazon’s AI spending plans lifted sector estimates. Nvidia’s CEO cited surging AI chip demand. AMD’s rally followed a weak revenue outlook earlier in the week.
Go toTop